alm2, you hit the nail on the head. Perfectly stated. I think the odds are very high that you really nailed exactly what happened in terms of this Panel's utter failure to do its sworn job in adjudicating this Appeal. It's nauseating and disgusting, and amounts to lawlessness.
alm2, This clearly places AMRN at a crossroad. Either JT will sell the company (mainly for the value of Europe at this point,) or else he will develop a branded generic Vascepa to counter the launch of a generic Vascepa as well as establish a sales force in Europe. Perhaps he will continue with the later while he leaves open the prospect of the former.
I honestly don't know if a branded Vascepa launch is even viable as from what has been posted previously generics are generally selected based on the relationship they have with pharmacy chains. Europe should be left to those BP with long standing relationships there. Common sense dictates that if AMRN truly GIA in Europe will be an uphill struggle. What would be the point when sales reps and structures are already in place?
The most logical solution is to sell the company...something which should have been done long ago. Perhaps there is a BP that would be a position to offer a branded generic Vascepa along with their other generic offerings and have relationships with pharmacies. My fear right now is that JT will attempt GIA!
News 
Market Data 
Discover 
